ADRs Slump; FLJ Group Declines 21%
This article was automatically generated by MarketWatch using technology from Automated Insights.
International stocks trading in New York closed lower on Tuesday, as the S&P/BNY Mellon index of American depositary receipts fell 1.2% to 163.59.
The European index fell 0.8% to 159.26. The Asian index declined 1.7% to 186.38. The Latin American index dropped 1.3% to 222.34, while the emerging-markets index fell 2.0% to 306.43.
FLJ Group, based in China, posted the largest decline, plummeting 21% to $1.58, followed by shares of China's Fresh2 Group, which tumbled 20% to 71 cents. Shares of China-based ATA Creativity Global tumbled 16% to 97 cents.
China's Akso Health Group was the biggest leader during the session, rocketing 53% to $1.13, and Sweden-based Eco Wave Power Global rocketed 22% to $1.51. I-Mab, which is based in China, rounded out the top three leaders on Tuesday, with shares surging 18% to $2.25.
Data source: Dow Jones Market Data, FactSet.
(END) Dow Jones Newswires
January 02, 2024 16:53 ET (21:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?